PCM
CDMO

Prelude Capital Management’s Avid Bioservices, Inc. Common Stock CDMO Stock Holding History

Prelude Capital Management’s Portfolio CDMO Stock Details CDMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,763
Closed -$528K – 1617
2024
Q4 		$528K Buy
+42,763
New +$490K 0.03% 579
2020
Q4 		– Sell
-400
Closed -$3K – 2114
2020
Q3 		$3K Buy
+400
New +$3.03K ﹤0.01% 1645
2019
Q2 		– Sell
-1,721
Closed -$7K – 2222
2019
Q1 		$7K Buy
+1,721
New +$7.02K ﹤0.01% 1602
2017
Q2 		– Sell
-11,486
Closed -$53K – 1910
2017
Q1 		$53K Sell
11,486
-3,185
-22% -$10.7K 0.01% 961
2016
Q4 		$32K Buy
14,671
+10,085
+220% +$23.6K ﹤0.01% 1212
2016
Q3 		$14K Buy
4,586
+3,757
+453% +$10.1K ﹤0.01% 1390
2016
Q2 		$2K Buy
+829
New +$2.31K ﹤0.01% 1516

Other funds holding CDMO

TCWM
Total Clarity Wealth Management St. Charles, Illinois $515M AUM 27.37% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Prelude Capital Management's CDMO Position: Q1 2025 in Review

Prelude Capital Management sold out of Avid Bioservices, Inc. Common Stock (CDMO) in Q1 2025, closing a stake of 42,763 shares — an estimated $528K sold.

Prelude Capital Management first reported a position in CDMO in Q2 2016 and held it in 7 quarters. The position peaked at $528K in Q4 2024. 2 funds tracked by Wall St. Rank hold CDMO as of Q1 2025.

  • Prelude Capital Management reported no remaining Avid Bioservices, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 42,763 Avid Bioservices, Inc. Common Stock shares in Q1 2025, an estimated $528K.
  • Prelude Capital Management first reported a position in Avid Bioservices, Inc. Common Stock in Q2 2016 and held it in 7 quarters.
  • Prelude Capital Management's Avid Bioservices, Inc. Common Stock position peaked at $528K in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Avid Bioservices, Inc. Common Stock as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.